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Abstract
Introduction: Stable heterosexual HIV-1 serodiscordant couples in Africa have high HIV-1 transmission rates and are a
critical population for evaluation of new HIV-1 prevention strategies. The Partners PrEP Study is a randomized, double-blind,
placebo-controlled trial of tenofovir and emtricitabine-tenofovir pre-exposure prophylaxis to decrease HIV-1 acquisition
within heterosexual HIV-1 serodiscordant couples. We describe the trial design and characteristics of the study cohort.
Methods: HIV-1 serodiscordant couples, in which the HIV-1 infected partner did not meet national guidelines for initiation
of antiretroviral therapy, were enrolled at 9 research sites in Kenya and Uganda. The HIV-1 susceptible partner was
randomized to daily oral tenofovir, emtricitabine-tenofovir, or matching placebo with monthly follow-up for 24–36 months.
Results: From July 2008 to November 2010, 7920 HIV-1 serodiscordant couples were screened and 4758 enrolled. For 62%
(2966/4758) of enrolled couples, the HIV-1 susceptible partner was male. Median age was 33 years for HIV-1 susceptible and
HIV-1 infected partners [IQR (28–40) and (26–39) respectively]. Most couples (98%) were married, with a median duration of
partnership of 7.0 years (IQR 3.0–14.0) and recent knowledge of their serodiscordant status [median 0.4 years (IQR 0.1–2.0)].
During the month prior to enrollment, couples reported a median of 4 sex acts (IQR 2–8); 27% reported unprotected sex and
14% of male and 1% of female HIV-1 susceptible partners reported sex with outside partners. Among HIV-1 infected
partners, the median plasma HIV-1 level was 3.94 log10 copies/mL (IQR 3.31–4.53) and median CD4 count was 496 cells/mL
(IQR 375–662); the majority (64%) had WHO stage 1 HIV-1 disease.
Conclusions: Couples at high risk of HIV-1 transmission were rapidly recruited into the Partners PrEP Study, the largest
efficacy trial of oral PrEP. (ClinicalTrials.gov NCT00557245)
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Introduction
Pre-exposure prophylaxis (PrEP), in which an HIV-1 susceptible
individual uses oral or topical antiretroviral medications for
prevention of HIV-1 acquisition, is a promising biomedical HIV-1
prevention strategy under investigation among diverse at-risk
populations worldwide [1]. Current efficacy studies have chosen
PrEP agents based on the antiretroviral medication tenofovir, as a
vaginal gel or as oral tenofovir disoproxil fumarate (TDF) and co-
formulated emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
Non-human primate studies have found that oral and topical
tenofovir-based PrEP can provide high levels of protection (70–
100%) when given prior to systemic or mucosal simian human
immunodeficiency virus (SHIV) challenge [2,3,4,5,6]. Recent clinical
trials have demonstrated promising efficacy of PrEP in decreasing
HIV-1 acquisition risk in populations receiving standard prevention
services. Coitally-associated use of a 1% tenofovir vaginal gel
decreased the risk of HIV-1 acquisition among heterosexual women
by 39% [7]. Among men who have sex with men (MSM), oral FTC/
TDF resulted in a 44% reduction in HIV-1 incidence [8]. Both of
these studies also showed increased levels of protection with better
adherence to PrEP. In contrast, a trial of daily oral FTC/TDF among
high-risk African women was terminated early for lack of efficacy,
with equal number of infections in the active and placebo arms [9].
HIV-1 susceptible individuals within HIV-1 serodiscordant
partnerships (in which one of the partners is infected with HIV-1
and the other is HIV-1 susceptible) are at high risk of HIV-1
acquisition [10]. A substantial proportion of new HIV-1 infections
in sub-Saharan Africa occur within stable heterosexual HIV-1
serodiscordant couples [11,12]. Recent data from HPTN 052, a
randomized, placebo-controlled, clinical trial conducted among
1,763 HIV-1 serodiscordant couples to assess HIV-1 prevention and
clinical benefits of immediate (CD4 350–550 cells/mL) versus
delayed (CD4,250 cells/mL) antiretroviral therapy found that
immediate initiation reduced HIV-1 transmission within the
partnership by 96% [13]. However, early initiation of therapy
would not address HIV-1 infections acquired from outside partners,
which have been seen in up to 30% of new infections occurring
within serodiscordant couples in prior prospective studies [14].
Therefore, complementary HIV-1 prevention interventions are
needed, such as PrEP, which may reduce risk of HIV-1 acquisition
in HIV-1 uninfected persons who have a known HIV-1 infected
partner who is not on antiretroviral therapy or who have risk from
outside partnerships of unknown HIV-1 serostatus.
We are conducting the Partners PrEP Study, a randomized
clinical trial of daily oral TDF and FTC/TDF PrEP to decrease
HIV-1 acquisition within HIV-1 serodiscordant heterosexual
couples, which is the only efficacy trial of PrEP in this high-risk
population. The potential for differential safety, cost and efficacy
for TDF and FTC/TDF as oral PrEP argues for evaluating both
as potential PrEP agents, ideally in parallel in a single clinical trial.
Unique to the Partners PrEP study is the inclusion of heterosexual
men, the potential to evaluate the efficacy of PrEP by level of HIV-
1 exposure (i.e., since HIV-1 plasma RNA concentrations are
measured at enrollment in the HIV-1 infected partner), and the
ability to assess whether drug resistance in breakthrough infections
is acquired or transmitted. Here, we describe the design of the trial
and baseline characteristics of the Partners PrEP Study cohort.
Methods
Ethics statement
The University of Washington Human Subjects Review
Committee and ethics review committees at collaborating
institutions at each of the study sites (Indiana University, Kenya
Medical Research Institute, Kenyatta National Hospital, Moi
University Teaching and Referral Hospital, Uganda National
Council of Science and Technology, Uganda Virus Research
Institute, United States Centers for Disease Control and
Prevention, University of California San Francisco) approved
the study protocol. All participants provided written informed
consent.
Study design
The Partners PrEP Study is a phase III, multi-site, randomized,
double-blind, parallel-arm, placebo-controlled trial of daily oral
TDF or FTC/TDF PrEP for the prevention of HIV-1 acquisition
by HIV-1 susceptible members of HIV-1 serodiscordant couples
(ClinicalTrials.gov number NCT00557245). HIV-1 susceptible
partners are assigned in a 1:1:1 ratio to one of three study arms:
TDF, FTC/TDF, or placebo (Figure 1). The primary study
objectives are to: 1) assess the efficacy of TDF and FTC/TDF
PrEP for preventing HIV acquisition in the susceptible partner
and 2) evaluate safety, each compared against the common
placebo arm. The study is end-point driven – i.e., 191 total HIV-1
seroconversion endpoint events (147 per each comparison of TDF
or FTC/TDF versus placebo) were determined prior to the trial to
be necessary to achieve 80% power with a one-sided alpha of
0.025. The trial’s primary objective is to evaluate effectiveness of
TDF and/or FTC/TDF PrEP for HIV-1 prevention, under the
assumptions that PrEP will decrease HIV-1 risk by 60% (the
alternative hypothesis, consistent with other trials of oral and
topical tenofovir-based PrEP, which were designed to detect
reductions in HIV-1 risk of 50–70% [1]), the lower bound of the
95% confidence interval for efficacy will exclude 30% reduced
HIV-1 risk (the null hypothesis for sample size calculations), and
that 10% of study follow-up time in HIV-1 susceptible women
assigned to the active study arms will be unexposed to PrEP due to
protocol-mandated study drug hold during pregnancy. A sample
size of approximately 4700 HIV-1 serodiscordant couples (1566 in
each treatment arm) was determined to be sufficient to achieve the
target number of study endpoints, with 24–36 months of follow-up
per participant, assuming up to 5% loss to follow-up per year and
an anticipated HIV-1 incidence of 2.75 per 100 person-years in
the placebo arm, as was observed in a recent cohort of African
HIV-1 serodiscordant heterosexual couples [14]. Gilead Sciences
(Foster City, CA) donated TDF, FTC/TDF, and placebo tablets
Figure 1. Study Schema.
doi:10.1371/journal.pone.0025828.g001
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for the study but did not have any role in the development of the
study protocol.
Recruitment and study eligibility criteria
The study is being conducted at nine research sites in Kenya
(Eldoret, Kisumu, Nairobi, and Thika) and Uganda (Jinja,
Kabwohe, Kampala, Mbale, and Tororo). HIV-1 serodiscordant
couples were recruited from a variety of sources, including HIV-1
voluntary counseling and testing (VCT) centers, antenatal clinics
and programs for prevention of mother-to-child HIV-1 transmis-
sion, referral from HIV-1 care providers including those
performing testing of partners of known HIV-1 infected
individuals engaged in HIV-1 care programs who were not
eligible for ART, and community promotion activities for couples’
VCT. Study recruitment occurred between July 2008 and
November 2010. The inclusion and exclusion criteria are detailed
in Table 1.
Study procedures
HIV-1 susceptible participants are followed monthly, for HIV-1
serologic testing, pregnancy testing (for women), provision of study
medication, adherence counseling, and behavioral risk assessment;
study product is discontinued in those who acquire HIV-1 or
during pregnancy. HIV-1 infected partners are followed quarterly,
with quarterly monitoring of HIV-1 clinical status and 6-monthly
CD4 counts. HIV-1 infected partners who become eligible for
initiation of antiretroviral therapy according to the national
guidelines of Kenya and Uganda during follow-up are actively
Table 1. Study Inclusion and Exclusion Criteria.
HIV-1 susceptible partners HIV-1 infected partners
Inclusion Criteria HIV-1 susceptible based on parallel negative HIV-1 rapid tests, at study screening
and enrollment visits
HIV-1 infected based on positive EIA
Age $18 and #65 years Age $18 years
Sexually active defined as six or more episodes of vaginal
intercourse with the HIV-1 infected study
partner in the 3 previous months
Sexually active defined as six or more episodes
of vaginal intercourse with the
HIV-1 infected study partner in
the 3 previous months
plan to remain in the relationship for the
study period
plan to remain in the relation-
ship for the study period
Adequate renal function creatinine clearance $60 ml/min, and CD4 cell count $250 cells/mL
serum creatinine #1.3 mg/dL (men)
or serum creatinine #1.1 mg/dL (women)
Adequate hepatic function total bilirubin #1.56 upper limit
of normal, and
No history of any clinical AIDS-defining diagnoses and
not otherwise meeting national guidelines for initiation
of antiretroviral therapy. In July 2010, Kenya guidelines
increased CD4 eligibility for initiation of antiretroviral
therapy from ,200 to ,350 cells/mL and study eligibility
was determined based on those updated guidelines
hepatic transaminases (ALT and
AST) ,26 upper limit of normal
Adequate hematologic function absolute neutrophil count .1,300/mm3 Able and willing to provide adequate locator information
for study retention purposes
platelets.125,000/mm3
hemoglobin.11 g/dL
No evidence of chronic active
hepatitis B infection
negative hepatitis B surface antigen test Able and willing to provide written informed consent
Able and willing to provide adequate locator information for study retention purposes
Able and willing to provide written informed consent
Exclusion Criteria Current pregnancy or planning to become pregnant during the study period Enrolled in an HIV-1 treatment trial
Current breastfeeding Current use of antiretroviral therapy
Repeated positive ($1+) urine dipstick tests for glycosuria or proteinuria
Ongoing therapy with: antiretroviral therapy; metformin; aminoglycoside
antibiotics; amphotericin B; cidofovir; systemic chemotherapeutic agents; other
agents with significant nephrotoxic potential
History of pathological bone fractures not related to trauma
Enrolled in another HIV-1 vaccine or prevention trial
Known plans to re-locate or travel away from the study site for more than two
consecutive months during study period
doi:10.1371/journal.pone.0025828.t001
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counseled to initiate treatment, referred, and linked into care at
local HIV-1 clinics. Pregnant HIV-1 infected women are actively
referred for antenatal care, including services for prevention of
mother-to-child HIV-1 transmission. All participants receive
regular individual and couples HIV-1 counseling, condoms,
contraception counseling and provision, risk reduction counseling,
and syndromic treatment for sexually transmitted infections
according to WHO guidelines. Uncircumcised HIV-1 susceptible
men are counseled about and referred for circumcision.
Laboratory procedures
Protocol-specified laboratory assays performed at study sites are
detailed in Table 2. For HIV-1 infected partners, plasma HIV-1
RNA concentrations from samples collected at enrollment were
quantified in batch testing at the University of Washington using
the Abbott Real-Time HIV-1 RNA assay (Abbott); the limit of
quantification was 80 copies/mL. Sites were enrolled in External
Quality Assurance (EQA) programs for protocol-specified labora-
tory tests.
Data collection and analysis
Demographic, behavioral, and clinical data were entered onto
standard case report forms, which were scanned using intelligent
character recognition (ICR) DataFax software (Clinical DataFax
Systems Inc., Hamilton, Canada) and double-verified by indepen-
dent data technicians. Data analyses were conducted using SAS
version 9.2 (SAS Institute, Cary, NC).
Results
Demographic and sexual risk behavior characteristics
From July 2008 to November 2010, a total of 7920 HIV-1
serodiscordant couples were screened for study eligibility, and
4758 were enrolled, for a screen-to-enroll ratio of 1.7:1. For 62%
of enrolled couples, the HIV-1 susceptible partner was male
(Table 3), and 56% of the couples were from Uganda. Although
98% of couples were married, with a median duration of the
partnership of 7.0 years (interquartile range [IQR] 3.0–14.0), most
couples had recently learned of their HIV-1 serodiscordant status
[median 0.4 years (IQR 0.1–2.0)]. A minority of couples (n = 331,
6%) had previously participated in another HIV-1 prevention
clinical trial (Partners in Prevention HSV/HIV Transmission
Study) conducted at 5 of the 9 research sites [14].
The median age of HIV-1 susceptible participants was 33 years
(IQR 28–40). HIV-1 susceptible partners reported a median of 4
sex acts (IQR 3–8) with their HIV-1 infected partner in the month
before enrollment, and 27% reported sex unprotected by condoms
Table 2. Study Site Laboratory Assays.
Kenya Uganda
Eldoret Kisumu Nairobi Thika Jinja Kampala Kabwohe Mbale Tororo
HIV-1 rapids Determine HIV 1/2 (Abbott/Inverness Medical) Determine HIV 1/2 (Abbott/Inverness Medical)
Unigold (Trinity Biotech) Bioline (Standard
Diagnostics)
Unigold (Trinity Biotech) HIV 1/2 STAT-PAK (Chembio
Diagnostic Systems)
HIV-1 enzyme
immunoassays*
Vironostika HIV Ag/Ab 4th gen (bioMe´rieux) Vironostika HIV Ag/Ab
4th gen (bioMe´rieux)
Vironostika HIV Uni-Form II plus
O – 3rd gen (bioMe´rieux)
Murex HIV Ag/AB Combo 4th gen (Abbott Murex) BioRad HIV 1/2 (Bio-Rad Laboratories) Murex HIV 1.2.0 AB 3rd gen
(Abbott Murex)
Urine dipstick
(protein, glucose)
Roche Combur
3 (Roche
Diagnostics)
Combina 10 M
(Human
Diagnostics)
Roche Combur 3
(Roche Diagnostics)
Roche Combur 3 (Roche Diagnostics) Urine-2
(Cypress
Diagnostics)
Combina 11
S (Human
Diagnostics)
Urine pregnancy QuickVue (Quidel Corporation) QuickVue (Quidel
Corporation)
Hexagon (Human
Diagnostics)
Acon (ACON
Laboratories)
CD4 BD FACSCalibur
(BD Biosciences)
BD FACSCount (BD Biosciences) BD FACSCalibur (BD Biosciences) BD FACSCount (BD
Biosciences)
Hematology Ac?T 5 diff CP (Beckman Coulter) Ac?T 5 diff CP (Beckman Coulter)
Chemistry** COBAS Integra 400 (Roche Diagnostics) COBAS Integra 400 (Roche Diagnostics)
Hepatitis B antigen Murex HBsAg version 3 (Abbott Murex) Murex HBsAg version 3 (Abbott Murex)
Hepatitis B antibody Murex antiHBs (Murex Biotech) Murex antiHBs (Murex Biotech)
Syphilis{{ Immutrep RPR
(Omega
Diagnostics)
BD Macro-Vue
RPR (BD
diagnostics)
Human RPR (Human
Diagnostics)
Human RPR (Human Diagnostics)
Immutrep TPHA
(Omega
Diagnostics)
Randox TPHA
(Randox
Laboratories)
Human TPHA Liquid
(Human Diagnostics)
Human TPHA Liquid (Human Diagnostics) Hexagon (Human
Diagnostics)
N. gonorrhoeae
C. trachomatis
APTIMA Combo 2 (Gen-Probe) APTIMA Combo 2 (Gen-Probe) COBAS Amplicor (Roche
Diagnostics)
T. vaginalis APTIMA TV TMA (Gen-Probe) APTIMA TV TMA (Gen-Probe) In Pouch TV (Biomed
Diagnostics)
*Jinja & Kampala used Vironostika 3rd gen until March 2010.
**Tororo & Mbale used Roche C111 until Sept 2010.
Kabwohe used {Immutrep RPR, and
{Determine Syphilis TP until May 2010.
doi:10.1371/journal.pone.0025828.t002
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with their study partner. At enrollment, 14% of HIV-1 susceptible
men reported sex with an outside partner in the month prior to
enrollment compared to 1% of women. Forty-seven percent of
HIV-1 susceptible women used contraception, most of which was
hormonal. At enrollment, 53% of HIV-1 susceptible men were
circumcised.
The median age of HIV-1 infected participants was 33 years
(IQR 26–39). The majority (64%) had WHO stage 1 HIV-1
disease, and 14% of HIV-1 infected women were pregnant at
enrollment. The median baseline CD4 count was 496 cells/mL
(IQR 375–662), and 81% had CD4 counts .350 cells/mL. The
median HIV-1 plasma RNA level was 3.94 log10 copies/mL (IQR
3.31–4.53). HIV-1 plasma RNA concentrations were significantly
higher in HIV-1 infected men versus women (median 4.17 log10
copies/mL verses 3.79 log10 copies/mL respectively; Mann-
Whitney-Wilcoxon p,0.0001). One-quarter of HIV-1 infected
partners had HIV-1 RNA ,2000 copies/mL, and 19% had HIV-
1 RNA .50,000 copies/mL.
The baseline prevalence of sexually transmitted infections (STIs)
was low. T. vaginalis was the most prevalent STI and was more
commonly detected in women (7% in HIV-1 susceptible and 9%
in HIV-1 infected women) than in men (3% in HIV-1 susceptible
and 2% in HIV-1 infected men).
Of 3162 HIV-1 serodiscordant couples who were screened for
the study but did not enroll, 2912 (92%) were not eligible, 208
(7%) were eligible but did not enroll, and 42 (1%) did not complete
Table 3. Baseline Characteristics of Enrolled HIV-1 Serodiscordant Couples (N = 4758).
Median (interquartile range) or N (%)
Couples with HIV-1 susceptible women (N=1792) Couples with HIV-1 susceptible men (N=2966)
HIV-1 infected male HIV-1 susceptible female HIV-1 infected female HIV-1 susceptible male
Demographic Characteristics
Age, years 39 (33–44) 33 (28–38) 29 (24–35) 34 (28–41)
18–24 34 (2%) 232 (13%) 794 (27%) 300 (10%)
25–34 498 (28%) 817 (46%) 1426 (48%) 1285 (43%)
35–44 822 (46%) 596 (33%) 626 (21%) 902 (30%)
$45 438 (24%) 147 (8%) 120 (4%) 479 (16%)
Education, years 7 (4–10) 6 (3–8) 7 (4–8) 8 (5–11)
Monthly income, any 1578 (88%) 1247 (70%) 1633 (55%) 2532 (85%)
Couple Characteristics
Uganda (vs. Kenya) 1207 (67%) 1453 (49%)
Married to study partner 1767 (99%) 2879 (97%)
Living with study partner 1763 (98%) 2897 (98%)
Years living with study partner 11 (5–18) 5 (2–10)
Number of children together 3 (1–5) 1 (0–3)
Years aware of HIV-1 serodiscordant status 0.7 (0.1–2.1) 0.3 (0.1–1.8)
Sexual Risk Behavior
Number of sex acts in prior month 4 (2–8) 4 (3–8)
Any unprotected sex acts in prior month 408 (23%) 862 (29%)
Any sex with outside partner in prior month 269 (15%) 10 (1%) 31 (1%) 406 (14%)
Clinical Characteristics
CD4 cell count/mL 457 (354–596) N/A 529 (396–704) N/A
HIV-1 plasma RNA, log10 copies/mL 4.17 (3.51–4.74) N/A 3.79 (3.20–4.38) N/A
WHO Stage 1 1048 (58%) N/A 1975 (67%) N/A
Stage 2 589 (33%) N/A 832 (28%) N/A
Stage 3 155 (9%) N/A 159 (5%) N/A
Circumcised (men only) 579 (32%) N/A N/A 1580 (53%)
Using contraception* N/A 841 (47%) 936 (32%) N/A
Pregnant N/A 0 (0%) 415 (14%) N/A
Sexually Transmitted Infections**
N. gonorrhoeae 1% (13/1688) 1% (21/1530) 2% (47/2568) 1% (21/2794)
C. trachomatis ,1% (7/1687) 1% (17/1530) 1% (19/2566) 2% (42/2799)
T. vaginalis 2% (28/1696) 7% (102/1612) 9% (251/2653) 3% (98/2807)
Syphilis (positive RPR & confirmatory test) 7% (117/1740) 6% (104/1737) 4% (115/2875) 4% (104/2879)
*Any contraceptive use includes: oral, injectable and implantable contraceptives, intrauterine device, hysterectomy or bilateral tubal ligation.
**Data on sexually transmitted infections available from a subset of participants.
doi:10.1371/journal.pone.0025828.t003
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screening. Major reasons for screening-out were CD4 count less
than 250 cells/mL (51%) in the HIV-1 infected partners (thus
meeting national criteria for antiretroviral therapy initiation), and
pregnancy (23%), breastfeeding (1%), or chronic active hepatitis B
infection (11%) among HIV-1 susceptible partners (Table 4). Less
than 5% of couples screened out for creatinine elevation,
glycosuria or proteinuria, which were exclusion criteria to
minimize potential renal toxicity from tenofovir exposure. Overall,
47% of couples had more than one reason for exclusion.
Discussion
East African HIV-1 serodiscordant couples in which the HIV-1
infected partner did not meet ART eligibility by national
guidelines, and who are at high risk of HIV-1 transmission, were
successfully enrolled into the Partners PrEP Study, the largest
efficacy trial of oral PrEP. The efficient accrual of nearly 4800
couples over a 28-month period, demonstrates the feasibility of
identifying and recruiting a high-risk heterosexual population to
determine the efficacy and safety of PrEP and other novel HIV-1
prevention interventions, and indicates that HIV-1 serodiscordant
couples are readily identified in rural and urban settings in sub-
Saharan Africa for targeted implementation and delivery of PrEP,
if efficacious.
Plasma HIV-1 RNA concentrations are a primary determinant
of the risk of transmission of HIV-1, which is highest when HIV-1
RNA concentrations are greater than 50,000 copies/mL [15,16];
we observed these RNA levels at enrollment in 19% of HIV-1
infected partners in our cohort. Other biologic and behavioral
correlates of sexual HIV-1 transmission include lack of male
circumcision, younger age, and unprotected sex. Approximately
one-third of HIV-1 susceptible partners were less than 30 years
old, half of HIV-1 susceptible men were uncircumcised, and more
than a quarter of couples reported sex unprotected by condoms. In
our prior studies of HIV-1 serodiscordant couples, these baseline
characteristics predicted higher HIV-1 incidence, in spite of
behavioral change during prospective follow-up associated with
ongoing risk-reduction counseling [14]. In recognition of these
risks, Partners PrEP Study sites provide condoms, counseling
about risk reduction, and referrals for HIV-1 susceptible
uncircumcised men to male circumcision providers throughout
follow-up. In long-term HIV-1 serodiscordant partnerships, the
risk of transmission decreases over time, which may reflect biologic
and behavioral factors [17,18]. For HIV-1 prevention trials that
require two to three years of intensive follow-up with a high
retention rate, the inclusion criteria leads to selection of stable
couples, as indicated by the median duration of partnership of
seven years in the Partners PrEP Study.
Previous studies have reported the high rates of transmission of
HIV-1 among serodiscordant couples who are unaware of their
serostatus [15]. Couples counseling and mutual disclosure of
serostatus have been temporally associated with increased condom
use and lower HIV-1 incidence in HIV-1 serodiscordant couples
[19,20]. Although self-reported condom use at study enrollment
was high in our cohort (73%), couples may have over-reported
condom use, as 14% of HIV-1 infected women were pregnant at
the time of study entry. Fertility rates are 4.9 and 6.7 per woman
in Kenya and Uganda [21], and couples report social and cultural
pressures to have children [22]. In settings where national
guidelines limit provision of ART to those with CD4 counts less
Table 4. Reasons for Screening Out of Ineligible HIV-1 Serodiscordant Couples (N= 2912).
Median (interquartile range) or N (%)
Characteristic
Couples with HIV-1 susceptible
women (N=1312)
Couples with HIV-1 susceptible men
(N=1600)
Reasons for ineligibility (HIV-1 infected partner)
CD4,250 cells/mL 784 (60%) 706 (44%)
History of AIDS defining illness 16 (1%) 18 (1%)
On antiretroviral therapy 7 (1%) 52 (3%)
Reasons for ineligibility (HIV-1 susceptible partner)
Pregnant or planning to become pregnant 66 (5%) N/A
Breastfeeding 16 (1%) N/A
Infected with hepatitis B virus (as determined by positive hepatitis B
surface antigen)
97 (7%) 237 (15%)
Not meeting clinical study eligibility criteria* 35 (3%) 63 (4%)
Not meeting renal study eligibility criteria 60 (5%) 48 (3%)
Not meeting other laboratory criteria** 355 (27%) 454 (28%)
Reasons for ineligibility (couple)
,6 sex acts with study partner in last 3 months 37 (3%) 63 (4%)
Planning to discontinue relationship 17 (1%) 39 (2%)
Planning to be away from study area .2 months during the study period 3 (,1%) 22 (1%)
Enrolled in other HIV-1 prevention or treatment trial 0 (0%) 0 (0%)
Other*** 36 (3%) 63 (4%)
*Clinical exclusion criteria are detailed in Table 1.
**Other laboratory criteria are: total bilirubin, hepatic transaminases, absolute neutrophil count, platelets, and hemoglobin as detailed in Table 1.
***Other reason (n = 99 total) included: not meeting behavioral or administrative criteria (n = 48); not found to be HIV-1 serodiscordant upon testing at the study site
(n = 26); and other clinical conditions/investigator decision (n = 25).
doi:10.1371/journal.pone.0025828.t004
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than 200 or 350 cells/mL, HIV-1 serodiscordant couples who
desire children could potentially benefit from PrEP. At study entry,
14% of HIV-1 susceptible men reported outside sexual partners; in
our previous work based on viral sequencing, we found that about
30% of incident HIV-1 infections occurring within HIV-1
serodiscordant couples were acquired from outside the primary
sexual partnership [14].
Approximately 15% of participants who screened out were
hepatitis B surface antigen (HBsAg) positive or met renal exclusion
criteria based on serum creatinine levels or proteinuria. Although
initial safety data from the 1% tenofovir gel and oral FTC/TDF
PrEP studies are encouraging, if tenofovir-based PrEP is shown to
be safe and efficacious in ongoing trials, PrEP safety will
subsequently need to be assessed in HIV-1 susceptible persons
with chronic active hepatitis B infection or pre-existing renal
dysfunction, as well as pregnant and breast-feeding women. Both
TDF and FTC have potent activity against hepatitis B virus
(HBV), and a small number of exacerbations (i.e., flares) of chronic
liver disease have been reported after withdrawal of these
medications in HIV-1 infected persons co-infected with HBV
[23,24]. Moreover, TDF treatment rarely has been associated with
decreases in proximal renal tubular function in HIV-1 infected
persons [25], and FTC requires dose adjustment for moderate
renal dysfunction. A recent systematic review and meta-analysis of
the renal safety of TDF in HIV-1 infected individuals found that
TDF use was associated with a statistically significant, but modest
loss of renal function (difference in creatinine clearance between
TDF users and controls of 3.92 mL/min), but not with increased
risk of severe proteinuria, hypophosphatemia or bone fractures
[26]. The long-term safety of TDF among HIV-1 uninfected
persons is unknown. If PrEP is implemented for the prevention of
HIV-1, a significant proportion of HIV-1 susceptible individuals,
including those with renal dysfunction and hepatitis B but also
pregnant and breastfeeding women, may be excluded from
receiving PrEP until bridging studies determine the safety of this
HIV-1 prevention intervention in these populations, and studies of
renal and bone safety of long-term PrEP use will be important.
In conclusion, a cohort of almost 4800 East African heterosex-
ual HIV-1 serodiscordant couples at high risk of HIV-1
transmission was efficiently recruited into a placebo-controlled
efficacy trial of daily oral TDF and FTC/TDF PrEP for HIV-1
prevention. Given the high risk of HIV-1 transmission among
serodiscordant couples, PrEP could be a cost-effective intervention
if the efficacy is modestly high, the highest-risk couples can be
targeted, and cost of delivery programs are comparable or lower
than for antiretroviral treatment programs [27]. If PrEP is
demonstrated to be safe and efficacious in the Partners PrEP
Study and other ongoing PrEP trials, implementation of PrEP
should be targeted to high-risk persons with normal renal function,
including HIV-1 serodiscordant couples.
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